VINCERX PHARMA INC. - COMMON STOCK

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

17 أبريل 2023 13:35:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

17 أبريل 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

28 مارس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

14 مارس 2023 16:35:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

06 فبراير 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

13 ديسمبر 2022 09:29:13 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

12 ديسمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

11 ديسمبر 2022 10:05:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

10 نوفمبر 2022 16:05:02 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

03 نوفمبر 2022 09:05:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

11 أغسطس 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

10 يونيو 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Provides Key Strategic Update

06 يونيو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

12 مايو 2022 16:05:02 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 أبريل 2022 13:05:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

29 مارس 2022 08:00:03 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 مارس 2022 16:35:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

09 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

03 فبراير 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

17 ديسمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire